MDGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Madrigal Pharmaceuticals Inc (MDGL) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators are mixed, options data shows limited bullish sentiment, and the financial performance has shown revenue growth but declining profitability. While hedge funds are increasing their positions, there are no significant catalysts or AI trading signals to suggest immediate action. A hold strategy is recommended until clearer positive signals emerge.
The stock's MACD is negative and expanding downward (-2.063), indicating bearish momentum. RSI is neutral at 43.378, suggesting no clear trend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near a key pivot point (523.845), with resistance at 535.926 and support at 511.765. Overall, the technical setup is mixed.
Hedge funds are significantly increasing their positions, with a 176.46% increase in buying over the last quarter. Barclays initiated coverage with an Overweight rating and a $964 price target, indicating long-term optimism.
No recent news or congress trading data. Analysts from BofA have lowered price targets twice recently, citing gross-to-net adjustments and limited impact from Q4 earnings. Financial performance shows declining profitability metrics, including net income, EPS, and gross margin.
In Q4 2025, revenue increased significantly by 210.77% YoY to $321.08M, but net income dropped by -1.42% YoY to -$58.58M. EPS declined by -5.90% YoY to -2.55, and gross margin fell by -4.43% YoY to 92.39. While revenue growth is strong, profitability metrics are deteriorating.
Barclays initiated coverage with an Overweight rating and a $964 price target, showing long-term optimism. However, BofA recently lowered its price target twice, from $595 to $570 and then to $529, maintaining a Neutral rating due to concerns over gross-to-net adjustments and limited impact from Q4 earnings.
